1. Home
  2. JFU vs NEPH Comparison

JFU vs NEPH Comparison

Compare JFU & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • JFU
  • NEPH
  • Stock Information
  • Founded
  • JFU 2006
  • NEPH 1997
  • Country
  • JFU China
  • NEPH United States
  • Employees
  • JFU N/A
  • NEPH N/A
  • Industry
  • JFU Finance: Consumer Services
  • NEPH Medical/Dental Instruments
  • Sector
  • JFU Finance
  • NEPH Health Care
  • Exchange
  • JFU Nasdaq
  • NEPH Nasdaq
  • Market Cap
  • JFU N/A
  • NEPH 16.8M
  • IPO Year
  • JFU 2019
  • NEPH 2004
  • Fundamental
  • Price
  • JFU $1.58
  • NEPH $1.99
  • Analyst Decision
  • JFU
  • NEPH Buy
  • Analyst Count
  • JFU 0
  • NEPH 1
  • Target Price
  • JFU N/A
  • NEPH $5.00
  • AVG Volume (30 Days)
  • JFU 20.6K
  • NEPH 4.1K
  • Earning Date
  • JFU 01-01-0001
  • NEPH 05-08-2025
  • Dividend Yield
  • JFU N/A
  • NEPH N/A
  • EPS Growth
  • JFU N/A
  • NEPH N/A
  • EPS
  • JFU 0.09
  • NEPH 0.01
  • Revenue
  • JFU $40,614,155.00
  • NEPH $14,162,000.00
  • Revenue This Year
  • JFU N/A
  • NEPH $9.23
  • Revenue Next Year
  • JFU N/A
  • NEPH $12.99
  • P/E Ratio
  • JFU $15.88
  • NEPH $283.07
  • Revenue Growth
  • JFU N/A
  • NEPH N/A
  • 52 Week Low
  • JFU $1.01
  • NEPH $1.36
  • 52 Week High
  • JFU $3.60
  • NEPH $2.55
  • Technical
  • Relative Strength Index (RSI)
  • JFU 65.75
  • NEPH 56.14
  • Support Level
  • JFU $1.33
  • NEPH $1.78
  • Resistance Level
  • JFU $1.75
  • NEPH $2.10
  • Average True Range (ATR)
  • JFU 0.19
  • NEPH 0.13
  • MACD
  • JFU 0.05
  • NEPH -0.01
  • Stochastic Oscillator
  • JFU 77.03
  • NEPH 76.09

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease.

Share on Social Networks: